

1. NAME OF THE MEDICINAL PRODUCT

LATA-T Latanoprost & Timolol Eye Drops, 0.005 & 0.5% w/v

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1 mL of solution contains 50 micrograms of latanoprost and 6.8 mg of timolol maleate corresponding to 5 mg of timolol.

Excipients with known effect:

Benzalkonium chloride 0.2 mg/mL

Sodium phosphate, monobasic, anhydrous Sodium phosphate, dibasic (containing total phosphates 6.3 mg/mL)

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Eye drops, solution.

The solution is a clear, colourless liquid.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

LATA-T is indicated in adults (including the elderly) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to another topical IOP lowering agent.

4.2 Posology and method of administration

Posology

Adults (including elderly people)

The recommended dose is one eye drop in the affected eye(s) once a day.

The use of LATA-T may be considered in patients who require both timolol and latanoprost, but it is unknown whether patients who are adequately controlled with timolol given twice daily plus latanoprost given once daily will be as well controlled with LATA-T given once daily. LATA-T should be used for the reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to another intraocular lowering pressure medication.

LATA-T should not be used more than once daily because latanoprost is most effective when given once daily. If there is an insufficient response to LATA-T, then consideration should be given to using the individual agents with timolol dosed twice daily.

If one dose is missed, treatment should continue with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.

If more than one topical ophthalmic drug is being used, they should be administered at least five minutes apart.

Contact lenses should be removed before instillation of the eye drops and may be reinserted after fifteen minutes (see section 4.4).

When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.

Use in children: Safety and effectiveness in children and adolescents have not been established.

4.3 Contraindications

LATA-T is contraindicated in patients with:

- Reactive airway disease including bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease.
- Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block not controlled with pace-maker, overt cardiac failure, or cardiogenic shock.
- Known hypersensitivity to latanoprost, timolol maleate, or any other component of the product.

4.4 Special warnings and precautions for use

General

This product contains benzalkonium chloride, which may be absorbed by contact lenses (see section 4.2).

Latanoprost:

Iris pigmentation changes

Latanoprost may gradually increase the brown pigment of the iris. The eye colour change is due to increased melanin content in the stromal melanocytes of the iris, rather than to an increase in the number of melanocytes. Typically the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. The change in iris colour is mild in the majority of cases and may not be detected clinically. The increase in iris pigmentation in one or both eyes has been documented predominantly in patients who have mixed-colour irides that contain the colour brown at baseline. Neither nevi nor freckles of the iris have been affected by treatment. No accumulation of pigment in the trabecular meshwork or elsewhere in the anterior chamber has been observed in clinical trials.

In a clinical trial designed to assess iris pigmentation over five years, there was no evidence of adverse consequences due to increased pigmentation even when administration of latanoprost continued. These results are consistent with post-marketing clinical experience since 1996. In addition, IOP reduction was similar in patients regardless of the development of increased iris pigmentation. Therefore, treatment with latanoprost can be continued in patients who develop increased iris pigmentation. These patients should be examined regularly and, depending on the clinical situation, treatment may be stopped.

Onset of increased iris pigmentation typically occurs within the first year of treatment, rarely during the second or third year, and has not been seen after the fourth year of treatment. The rate of progression of iris pigmentation decreases with time and is stable by five years. The effects of increased pigmentation beyond five years have not been evaluated. During clinical

trials, the increase in brown iris pigment has not been shown to progress further upon discontinuation of treatment, but the resultant colour change may be permanent.

The potential for heterochromia exists for patients receiving unilateral treatment.

Eyelid and eyelash changes

Eyelid skin darkening, which may be reversible, has been reported in association with the use of latanoprost.

Latanoprost may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, pigmentation, and number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are reversible upon discontinuation of treatment.

Macular oedema

Macular oedema, including cystoid macular oedema, has been reported during treatment with latanoprost. These reports have mainly occurred in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular oedema. Caution is recommended when using latanoprost in these patients.

Glaucoma

There is no documented experience with latanoprost-timolol in inflammatory, neovascular, chronic angle closure or congenital glaucoma, in open angle glaucoma of pseudophakic patients and in pigmentary glaucoma. Latanoprost has no or little effect on the pupil but there is no documented experience in acute attacks of closed angle glaucoma. It is recommended, therefore, that latanoprost-timolol should be used with caution in these conditions until more experience is obtained.

Herpetic keratitis

Latanoprost should be used with caution in patients with a history of herpetic keratitis, and should be avoided in cases of active herpes simplex keratitis and in patients with a history of recurrent herpetic keratitis specifically associated with prostaglandin analogues.

Timolol Maleate:

Cardiovascular and respiratory reactions

The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with their topical administration. Patients with a history of severe cardiac disease should be monitored closely for signs of cardiac failure. The following cardiac and respiratory reactions may occur after topical application of timolol maleate:

- aggravation of Prinzmetal's angina
- aggravation of peripheral and central circulatory disorders
- hypotension
- cardiac failure resulting in death
- severe respiratory reactions, including fatal bronchospasm in patients with asthma
- bradycardia

Due to its negative effect on conduction time, beta-blockers should only be given with caution to patients with first degree heart block.

Patients with severe peripheral circulatory disturbance/disorders (i.e., severe forms of Raynaud's disease or Raynaud's syndrome) should be treated with caution.

Timolol maleate should be used with caution, in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk.

A gradual withdrawal of beta-adrenergic blocking agents prior to major surgery should be considered. Beta-adrenergic blocking agents impair the ability of the heart to respond to beta-adrenergically mediated reflex stimuli, which may augment the risk of general anaesthesia in surgical procedures. Prolonged severe hypotension during anaesthesia and difficulty restarting and maintaining the heartbeat have been reported. During surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists.

Beta-blocking ophthalmological preparations may block systemic beta-agonist effects e.g., of adrenaline. The anaesthesiologist should be informed when the patient is receiving timolol.

Hypoglycaemia

Beta-adrenergic blocking agents may increase the hypoglycaemic effect of agents used to treat diabetes, and can mask the signs and symptoms of hypoglycaemia. They should be used with caution in patients with spontaneous hypoglycaemia or diabetes (especially those with labile diabetes), who are receiving insulin or oral hypoglycaemic agents.

Hyperthyroidism

Therapy with beta-adrenergic blocking agents may mask certain signs and symptoms of hyperthyroidism. Abrupt withdrawal of therapy may precipitate a worsening of this condition.

Hypersensitivity reactions

When treated with beta-adrenergic blocking agents, patients with a history of atopy or severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens. They may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions.

Myasthenia gravis

Timolol maleate has been reported to rarely increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms (e.g., diplopia, ptosis, generalised weakness).

Choroidal detachment and corneal disease

Choroidal detachment after filtration procedures has been reported with the administration of ocular hypotensive agents.

Ophthalmic beta-blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution.

4.5. Interaction with Other Medicinal Products and Other Forms of Interaction

Specific medicinal product interaction studies have not been performed with latanoprost-timolol maleate.

The effect on intraocular pressure or the known effects of systemic beta-blockade may be potentiated when latanoprost-timolol maleate is given to patients already receiving an oral beta-adrenergic blocking agent, and the use of two or more topical beta-adrenergic blocking agents is not recommended.

There have been reports of paradoxical elevations in IOP following the concomitant ophthalmic administration of two prostaglandin analogues. Therefore, the use of two or more prostaglandins, prostaglandin analogues, or prostaglandin derivatives is not recommended.

Mydriasis has occasionally been reported when timolol maleate was given with epinephrine.

The potential exists for additive effects resulting in systemic hypotension and/or marked bradycardia when timolol maleate is administered with:

- calcium channel blockers
- catecholamine-depleting drugs or beta-adrenergic blocking agents
- antiarrhythmics (including amiodarone)
- digitalis glycosides
- guanethidine

Potentiated systemic beta blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine) and timolol.

Beta-adrenergic blocking agents may increase the hypoglycaemic effect of agents used to treat diabetes (see section 4.4).

4.6. Fertility, Pregnancy and Lactation

Fertility

Latanoprost has not been found to have any effect on male or female fertility in animal studies. Reproduction and fertility studies of timolol maleate in rats demonstrated no adverse effect on male or female fertility at doses up to 21,000 times the systemic exposure following the maximum recommended human ophthalmic dose (see section 5.3 *Impairment of Fertility* - **Latanoprost and Timolol Maleate**).

Pregnancy

Latanoprost:

There are no adequate and well-controlled studies in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.

Timolol:

Well-controlled epidemiological studies with systemic use of beta-blockers did not indicate malformative effects, but some pharmacological effects such as bradycardia have already been observed in foetuses or neonates.

Lactation

Latanoprost and its metabolites may pass into breast milk. Timolol maleate has been detected in human milk following oral and ocular drug administration. Because of the potential for serious adverse reactions in nursing infants, LATA-T should therefore be used with caution in nursing women.

4.7. Effects on Ability to Drive and Use Machines

Instillation of eye drops may cause transient blurring of vision. Until this has resolved, patients should not drive or use machines.

4.8. Undesirable Effects

Latanoprost/Timolol Maleate:

Table 1. ADRs by SOC and CIOMS frequency category for latanoprost/timolol maleate listed in order of decreasing medical seriousness or clinical importance within each frequency category and SOC

System Organ Class	Common ≥1/100 to <1/10	Uncommon ≥1/1,000 to <1/100	Frequency Not Known (cannot be estimated from the available data)
Nervous system disorders	Headache		
Eye disorders	Corneal disorder, Keratitis, Conjunctivitis, Blepharitis, Eye pain, Eye irritation, Eye hyperaemia, Iris hyperpigmentation	Conjunctival disorder, Hypertrichosis (eyelash and vellus hair changes of the eyelid; increased length, thickness, pigmentation, and number of eyelashes), Photophobia	Abnormal vision, Errors of refraction
Vascular disorders	Hypertension		
Skin and subcutaneous tissue disorders		Rash, Skin disorder	

Table 2. Adverse events by SOC and CIOMS frequency category for latanoprost/timolol listed in order of decreasing medical seriousness or clinical importance within each frequency category and SOC

System Organ Class	Very Common ≥1/10	Common ≥1/100 to <1/10	Uncommon ≥1/1,000 to <1/100
Infections and infestations		Upper respiratory tract infection	Infection, Sinusitis
Metabolism and nutrition disorders			Diabetes mellitus, Hypercholesterolemia
Psychiatric disorders			Depression
Eye disorders	Cataract	Visual field defect	
Musculoskeletal and connective tissue disorders			Arthritis

Latanoprost:

Table 3. ADRs by SOC and CIOMS frequency category for latanoprost monotherapy listed in order of decreasing medical seriousness or clinical importance within each frequency category and SOC.

System Organ Class	Common ≥1/100 to <1/10	Uncommon ≥1/1,000 to <1/100	Rare ≥1/10,000 to <1/1,000	Frequency Not Known (cannot be estimated from the available data)
Infections and				Herpetic keratitis*

infestations				
Nervous system disorders		Dizziness*		
Eye disorders	Eye irritation (burning, grittiness, itching, stinging and foreign body sensation), Eyelash and vellus hair changes of the eyelid (increased length, thickness, pigmentation, and number of eyelashes)*	Macular oedema including cystoid macular oedema*, Uveitis*, Photophobia*, Eyelid oedema	Corneal oedema*, Iritis*	Corneal erosion*, Punctate keratitis*, Pseudophthalmos of ocular conjunctiva*, Trichiasis*, Vision blurred*, Localised skin reaction on the eyelids*, Iris cyst*, Periorbital and lid changes resulting in deepening of the eyelid sulcus*, Darkening of palpebral skin of eyelids*
Cardiac disorders		Angina*, Palpitations*		Angina unstable*
Respiratory, thoracic and mediastinal disorders		Asthma*, Dyspnoea*		Acute asthma attacks*, Asthma aggravation*
Gastrointestinal disorders		Nausea*	Vomiting*	
Skin and subcutaneous tissue disorders		Rash	Pruritus*	
Musculoskeletal and connective tissue disorders		Myalgia*, Arthralgia*		
General disorders and administration site conditions		Chest pain*		
*ADR identified post-marketing				

Timolol Maleate (Ocular Administration):

Additional adverse drug reactions have been observed with the single component timolol maleate when used by ocular administration

Table 4. Adverse Drug Reaction: Timolol Maleate (ocular administration)

Adverse Drug Reactions	System Organ Class
Immune system disorders	Signs and symptoms of systemic allergic reactions including anaphylaxis; angioedema; urticaria; pruritus; localised and generalised rash
Metabolism and nutrition disorders	Masked symptoms of hypoglycaemia in diabetic patients; anorexia
Psychiatric disorders	Behavioural changes and psychic disturbances including, confusion, hallucinations, anxiety, disorientation, nervousness, and memory loss; insomnia; depression; nightmares

Nervous system disorders	Cerebral vascular accident; cerebral ischemia; dizziness; increase in signs and symptoms of myasthenia gravis; paraesthesia; somnolence; headache; syncope
Eye disorders	Cystoid macular oedema; choroidal detachment following filtration surgery; corneal erosion; keratitis; diplopia; decreased corneal sensitivity; signs and symptoms of ocular irritation (e.g., burning, stinging, itching, tearing, redness); dry eyes; ptosis; blepharitis; visual disturbances including refractive changes; vision blurred
Ear and labyrinth disorders	Tinnitus
Cardiac disorders	Cardiac arrest; cardiac failure; heart block; atrioventricular block; congestive heart failure; worsening of angina pectoris; arrhythmia; bradycardia; palpitation
Vascular disorders	Claudication; cold hands and feet; hypotension; Raynaud's phenomenon
Respiratory, thoracic and mediastinal disorders	Respiratory failure; pulmonary oedema; bronchospasm (predominantly in patients with pre-existing bronchospastic disease); cough; dyspnoea; nasal congestion
Gastrointestinal disorders	Retroperitoneal fibrosis; abdominal pain; vomiting; diarrhoea; dry mouth; dysgeusia; dyspepsia; nausea
Skin and subcutaneous tissue disorders	Rash; psoriasiform rash; pseudopemphigoid; exacerbation of psoriasis; alopecia
Musculoskeletal and connective tissue disorders	Myalgia; Systemic lupus erythematosus
Reproductive system and breast disorders	Sexual dysfunction; decreased libido; impotence; Peyronie's disease
General disorders and administration site conditions	Chest pain; oedema; asthenia; fatigue

Adverse reactions reported with the use of eye drops containing phosphate buffers.

Cases of corneal calcification have been reported very rarely in association with the use of phosphate-containing eye drops in some patients with significantly damaged corneas.

4.9. Overdose

If overdosage with latanoprost-timolol occurs, treatment should be symptomatic.

Information concerning overdose with the individual components is provided below:

Latanoprost:

Apart from ocular irritation and conjunctival hyperaemia, no other ocular adverse effects are known if latanoprost is overdosed.

If latanoprost is accidentally ingested orally the following information may be useful: One 2.5 ml bottle contains 125 micrograms latanoprost. More than 90% is metabolised during the first pass through the liver. Intravenous infusion of 3 mcg/kg in healthy volunteers induced no symptoms, but a dose of 5.5-10 mcg/kg caused nausea, abdominal pain, dizziness, fatigue, hot flushes and sweating. These events were mild to moderate in severity and resolved without treatment, within 4 hours after terminating the infusion. In patients with moderate bronchial asthma, bronchoconstriction was not induced by latanoprost when applied topically on the eyes in a dose of seven times the clinical dose of latanoprost (see section **5.3 Latanoprost: Systemic/Ocular Effects**).

Timolol Maleate:

There have been reports of inadvertent overdosage with timolol-maleate ophthalmic solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as

dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest (see section **4.8 Timolol Maleate [Ocular Administration]**).

An *in vitro* haemodialysis study demonstrated that timolol was readily dialysed from human plasma or whole blood.

A study with renal failure patients demonstrated that timolol was not readily dialysed.

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic Properties

Mechanism of action

Product consists of two components: latanoprost and timolol maleate. These two components decrease elevated intraocular pressure (IOP) by different mechanisms of action and the combined effect results in additional IOP reduction compared to either compound administered alone.

Latanoprost:

The active substance latanoprost, a prostaglandin F_{2α} analogue, is a selective prostanoid FP receptor agonist that reduces the intraocular pressure by increasing the outflow of aqueous humour, primarily through the uveoscleral route and also through the trabecular meshwork.

Clinical trials have shown that latanoprost has no significant effect on the production of aqueous humour. Latanoprost has not been found to have any effect on the blood-aqueous barrier.

Latanoprost has not induced fluorescein leakage in the posterior segment of pseudophakic human eyes during short-term treatment.

Latanoprost in clinical doses has not been found to have any significant pharmacological effects on the cardiovascular or respiratory system.

Timolol Maleate:

Timolol maleate is a beta-1 and beta-2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anaesthetic (membrane-stabilising) activity.

Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.

Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous (see section **4.3** and section **4.4 Timolol Maleate**).

Timolol maleate ophthalmic solution, when applied topically on the eye, has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic nerve damage.

The precise mechanism of the ocular hypotensive action of timolol maleate is not clearly established at this time. Tonography and fluorophotometry studies in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies a slight increase in outflow facility was also observed.

Clinical effects

In dose finding studies, latanoprost-timolol maleate produced significantly greater decreases in mean diurnal IOP compared to latanoprost and timolol maleate administered once daily as monotherapy. In two well-controlled, double-masked, six-month clinical studies, the IOP reducing effect of latanoprost-timolol maleate was compared with latanoprost and timolol maleate monotherapy in patients with an IOP of at least 25 mm Hg or greater. Following a 2 to 4 week run-in with timolol maleate (mean decrease in IOP from enrolment of 5 mm Hg), additional decreases in mean diurnal IOP of 3.1, 2.0 and 0.6 mm Hg were observed after 6 months of treatment with latanoprost-timolol maleate and latanoprost and timolol maleate (twice daily), respectively. The IOP lowering effect of latanoprost-timolol maleate was maintained in a 6 month open label extension of these studies.

Onset of action of latanoprost-timolol maleate is within one hour and maximal effect occurs within six to eight hours. Adequate IOP reducing effect has been shown to be present up to 24 hours post-dosage after multiple treatments.

5.2. Pharmacokinetic Properties

Latanoprost-Timolol Maleate:

No pharmacokinetic interactions between latanoprost and timolol maleate were observed although there was an approximate two-fold increased concentration of the acid of latanoprost in aqueous humour 1 to 4 hours after administration of latanoprost-timolol maleate compared to monotherapy.

Latanoprost:

Absorption

Latanoprost is absorbed through the cornea where the isopropyl ester prodrug is hydrolysed to the acid form to become biologically active. Studies in man indicate that the peak concentration in the aqueous humour, approximately 15-30 ng/ml, is reached about two hours after topical administration.

Distribution

The distribution volume in humans is 0.16 ± 0.02 l/kg. The acid of latanoprost can be measured in aqueous humour during the first four hours, and in plasma only during the first hour after local administration. The acid of latanoprost has a plasma protein binding of 87%.

Metabolism

Latanoprost, an isopropyl ester prodrug, is hydrolysed by esterases in the cornea to the biologically active acid. The active acid of latanoprost reaching the systemic circulation is primarily metabolised by the liver to the 1, 2-dinor and 1, 2, 3, 4-tetranor metabolites via fatty acid β -oxidation.

Excretion

The elimination of the acid of latanoprost from human plasma is rapid ($t_{1/2}=17$ min) after both intravenous and topical administration. Systemic clearance is approximately 7 ml/min/kg. Following hepatic β -oxidation, the metabolites are mainly eliminated via the kidneys. Approximately 88% and 98% of the administered dose is recovered in the urine after topical and intravenous dosing, respectively.

Timolol Maleate:

The maximum concentration of timolol maleate in the aqueous humour is reached about one hour after topical administration of eye drops. Part of the dose is absorbed systemically and a maximum plasma concentration of 1 ng/ml is reached 10-20 minutes after topical administration of one eye drop to each eye once daily (300 micrograms/day). The half-life of timolol maleate in plasma is about six hours. Timolol is extensively metabolised in the liver. The metabolites are excreted in the urine together with some unchanged timolol maleate.

5.3. Preclinical Safety Data

The ocular and systemic safety profile of the individual components is well established. No adverse ocular or systemic effects were seen in rabbits treated topically with the fixed combination or with concomitantly administered latanoprost and timolol ophthalmic solutions. Safety pharmacology, genotoxicity and carcinogenicity studies with each of the components revealed no special hazards for humans. Latanoprost did not affect corneal wound healing in the rabbit eye, whereas timolol inhibited the process in the rabbit and the monkey eye when administered more frequently than once a day.

Latanoprost:

Systemic/Ocular Effects

The ocular as well as systemic toxicity of latanoprost has been investigated in several animal species. Generally, latanoprost is well tolerated with a safety margin between clinical ocular dose and systemic toxicity of at least 1000 times. High doses of latanoprost, approximately 100 times the clinical dose/kg body weight, administered intravenously to unanaesthetised monkeys have been shown to increase the respiration rate probably reflecting bronchoconstriction of short duration. In monkeys, latanoprost has been infused intravenously in doses of up to 500 mcg/kg without major effects on the cardiovascular system. In animal studies, latanoprost has not been found to have sensitising properties.

In the eye, no toxic effects have been detected with doses of up to 100 micrograms/eye/day in rabbits or monkeys (clinical dose is approximately 1.5 micrograms/eye/day). Latanoprost has no or negligible effects on the intraocular blood circulation when used at the clinical dose and studied in monkeys.

In chronic ocular toxicity studies, administration of latanoprost 6 micrograms/eye/day has also been shown to induce increased palpebral fissure. This effect is reversible and occurs at doses above the clinical dose level. The effect has not been seen in humans.

Carcinogenesis

Carcinogenicity studies in mice and rats were negative.

Mutagenesis

Latanoprost was found negative in reverse mutation tests in bacteria, gene mutation in mouse lymphoma and mouse micronucleus test. Chromosome aberrations were observed *in vitro* with human lymphocytes. Similar effects were observed with prostaglandin F2 α , a naturally occurring prostaglandin, and indicates that this is a class effect.

Additional mutagenicity studies on *in vitro/in vivo* unscheduled DNA synthesis in rats were negative and indicate that latanoprost does not have mutagenic potency.

Impairment of Fertility

Latanoprost has not been found to have any effect on male or female fertility in animal studies. In the embryotoxicity study in rats, no embryotoxicity was observed at intravenous doses (5, 50 and 250 micrograms/kg/day) of latanoprost. However, latanoprost induced embryoletal effects in rabbits at doses of 5 micrograms/kg/day and above. Latanoprost has been shown to cause embryofoetal toxicity in rabbits, characterised by increased incidences of late resorption and abortion and reduced foetal weight when given in intravenous doses approximately 100 times the human dose.

Teratogenesis

No teratogenic potential has been detected.

Timolol Maleate:

Carcinogenesis

In a two-year study of timolol maleate administered orally to rats, there was a statistically significant increase in the incidence of adrenal pheochromocytomas in male rats administered 300 mg/kg/day (approximately 42,000 times the systemic exposure following the maximum recommended human ophthalmic dose). Similar differences were not observed in rats administered oral doses equivalent to approximately 14,000 times the maximum recommended human ophthalmic dose.

In a lifetime oral study in mice, there were statistically significant increases in the incidence of benign and malignant pulmonary tumours, benign uterine polyps and mammary adenocarcinomas in female mice at 500 mg/kg/day (approximately 71,000 times the systemic exposure following the maximum recommended human ophthalmic dose), but not at 5 or 50 mg/kg/day (approximately 700 or 7,000, respectively, times the systemic exposure following the maximum recommended human ophthalmic dose). In a subsequent study in female mice, in which post-mortem examinations were limited to the uterus and the lungs, a statistically significant increase in the incidence of pulmonary tumours was again observed at 500 mg/kg/day.

The increased occurrence of mammary adenocarcinomas was associated with elevations in serum prolactin which occurred in female mice administered oral timolol maleate at 500 mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents that elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumours has been established in humans.

Mutagenesis

Timolol maleate was devoid of mutagenic potential when tested *in vivo* (mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and *in vitro* in a neoplastic cell transformation assay (up to 100 mcg/ml). In Ames tests the highest concentrations of timolol maleate employed, 5,000 or 10,000 mcg/plate, were associated with statistically significant elevations of revertants observed with tester strain TA100 (in seven replicate assays), but not in the remaining three strains. In the assays with tester strain TA100, no consistent dose response relationship was observed, and the ratio of test to control revertants did not reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test.

Impairment of Fertility

Reproduction and fertility studies in rats demonstrated no adverse effect on male or female fertility at doses up to 21,000 times the systemic exposure following the maximum recommended human ophthalmic dose.

Teratogenesis

Teratogenicity studies with timolol maleate in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of foetal malformations. Although delayed foetal ossification was observed at this dose in rats, there were no adverse effects on post-natal development of offspring. Doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of foetal resorptions. Increased foetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium chloride
Benzalkonium chloride
Sodium phosphate, monobasic, monohydrate
Sodium phosphate, dibasic, anhydrous
Hydrochloric acid solution (to be adjusted to pH 6.0)
and/or
Sodium hydroxide solution (to be adjusted to pH 6.0)
Water for injection

6.2 Incompatibilities

In vitro studies have shown that precipitation occurs when eye drops containing thiomersal are mixed with LATA-T. If such drugs are used concomitantly with LATA-T, eye drops should be administered at least five minutes apart.

6.3 Shelf life

Before first opening: 2 years

After opening the container: 4 weeks

6.4 Special precautions for storage

Before first opening: Store in a refrigerator (2°C – 8°C).

After first opening: Do not store above 25°C. Use within 4 weeks (see section 6.3).

Keep the vial in the outer carton in order to protect it from light.

6.5 Nature and contents of container

Dropper (5 mL) made of polyethylene with screw cap and polyethylene seal.

Each vial contains 2.5 mL of solution for eye drops.

Package sizes: 1 x 2.5 mL, 3 x 2.5 mL, 6 x 2.5 mL

Not all pack sizes may be available.

6.6 Special precautions for disposal and other handling

The safety ring must be removed before use.

7. PRODUCT OWNER

ARISTOVISION SG PTE LTD

100 Tras Street #09-01 100AM Singapore 079027

8. REGISTRATION NUMBER

SIN XXX

9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION

XX

9. DATE OF REVISION OF THE TEXT

14 May 2024